Ami Lifesciences Pvt. Ltd. Company Profile

Background

Established in 1994 and headquartered in Vadodara, Gujarat, India, Ami Lifesciences Pvt. Ltd. is a prominent manufacturer and exporter of Active Pharmaceutical Ingredients (APIs) and advanced pharmaceutical intermediates. The company serves a global clientele across more than 60 countries, including regions such as North America, Europe, East Asia, and the Middle East. Ami Lifesciences is committed to delivering high-quality and affordable APIs, aiming to be a leading pharmaceutical company in India and a significant global player.

Key Strategic Focus

Ami Lifesciences specializes in the production of APIs and pharmaceutical intermediates, catering to therapeutic areas such as cardiovascular, anti-diabetics, central nervous system (CNS), and respiratory conditions. The company emphasizes custom synthesis and contract manufacturing, offering tailored solutions to pharmaceutical companies worldwide. Its manufacturing facility in Karakhadi, Vadodara, is compliant with international standards, including EU-GMP, WHO-GMP, and certifications from regulatory bodies like KFDA, TFDA, COFEPRIS, and IRAN MOH.

Financials and Funding

For the financial year ending March 31, 2023, Ami Lifesciences reported operating revenue exceeding INR 500 crore. The company's net worth increased by 2.98%, while EBITDA decreased by 24.02%. Total assets saw a slight decline of 0.46%, and liabilities increased by 6.32%. The debt-to-equity ratio stood at 0.48, and the return on equity was 2.92%.

Pipeline Development

Ami Lifesciences offers a diverse portfolio of APIs and intermediates, including products like desvenlafaxine succinate, doxofylline, choline fenofibrate, benfotiamine, acebrophylline, benzonatate, azilsartan medoxomil potassium salt, febuxostat, and mesalazine. The company is actively involved in research and development to expand its product offerings and address unmet patient needs in various therapeutic areas.

Technological Platform and Innovation

Ami Lifesciences has established a state-of-the-art R&D center in Vadodara, equipped with modern laboratories and complemented by an extensive library and online research facilities. The company focuses on developing new, environmentally friendly processes for both existing and novel molecules in the fields of fine chemicals, intermediates, and APIs. Additionally, Ami Lifesciences offers custom synthesis services, leveraging its expertise in chemical synthesis to supply specialty chemicals with Drug Master Files exclusively and reliably on a long-term basis.

Leadership Team

The leadership team at Ami Lifesciences includes:

Girishkumar Limbabhai Chovatia: Serving as a Director since December 24, 2002, he has been instrumental in steering the company's strategic direction and growth.

Kiranben Girishbhai Chovatia: Appointed as a Director on January 24, 2024, she brings valuable insights and leadership to the organization.

Ameeshi Girishkumar Chovatia: Joined the board as a Director on December 21, 2022, contributing to the company's strategic initiatives.

Hirenkumar Sureshchandra Shah: Appointed as a Director on December 27, 2023, he adds to the company's leadership strength.

Virendrakumar H Thakrar: Joined as a Director on January 24, 2024, bringing his expertise to the board.

Kirit Revashankar Dharawat: Serving as Chief Financial Officer (CFO) since January 24, 2024, overseeing the company's financial operations.

Tarnnum Hasnain Mulla: Appointed as Company Secretary on October 21, 2022, ensuring compliance and governance.

Competitor Profile

Market Insights and Dynamics: The global API market is experiencing significant growth, driven by increasing demand for generic and specialty pharmaceuticals. Key factors include the rising prevalence of chronic diseases, an aging population, and the expansion of the pharmaceutical industry in emerging markets.

Competitor Analysis: Ami Lifesciences faces competition from several key players in the API manufacturing sector, including:

SynGene International Ltd: A leading contract research and manufacturing organization offering integrated services to pharmaceutical companies.

GVK Biosciences Private Limited: Provides contract research and development services, including API manufacturing.

Sigma-Aldrich Chemicals Pvt Ltd: Offers a wide range of chemicals and APIs for various industries.

BLD Pharmatech India Private Limited: Specializes in the production of pharmaceutical intermediates and APIs.

Strategic Collaborations and Partnerships

Ami Lifesciences has established significant collaborations and partnerships to strengthen its market position and innovation capacity. The company has a notable presence in custom synthesis and contract manufacturing, offering tailored solutions to pharmaceutical companies worldwide. Its manufacturing facility in Karakhadi, Vadodara, is compliant with international standards, including EU-GMP, WHO-GMP, and certifications from regulatory bodies like KFDA, TFDA, COFEPRIS, and IRAN MOH.

Operational Insights

Ami Lifesciences' strategic considerations include:

Market Position: Leveraging its extensive product portfolio and global reach to maintain a competitive edge.

Competitive Advantages: Emphasis on quality assurance, regulatory compliance, and customer-centric services to differentiate from competitors.

Supply Chain Management: Establishing a robust supply chain with reliable suppliers and efficient logistics to ensure timely delivery and cost-effectiveness.